These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2310695)

  • 1. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia.
    Jaubert J; Martiat P; Dowding C; Ifrah N; Goldman JM
    Br J Haematol; 1990 Jan; 74(1):30-5. PubMed ID: 2310695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene.
    Mills KI; Sproul AM; Leibowitz D; Burnett AK
    Leukemia; 1991 Nov; 5(11):937-41. PubMed ID: 1961034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of M-BCR breakpoint sites on the duration of chronic phase in 100 patients with chronic myelocytic leukemia.
    Tanaka K; Hashimoto T; Oguma N; Dohy H; Kamada N
    Cancer Genet Cytogenet; 1993 Oct; 70(1):39-47. PubMed ID: 8221611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.
    Grossman A; Silver RT; Arlin Z; Coleman M; Camposano E; Gascon P; Benn PA
    Am J Hum Genet; 1989 Nov; 45(5):729-38. PubMed ID: 2683759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.
    Eisenberg A; Silver R; Soper L; Arlin Z; Coleman M; Bernhardt B; Benn P
    Leukemia; 1988 Oct; 2(10):642-7. PubMed ID: 3172841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis.
    Przepiorka D
    Cancer Genet Cytogenet; 1988 Nov; 36(1):117-22. PubMed ID: 3203293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
    Cortes JE; Talpaz M; Beran M; O'Brien SM; Rios MB; Stass S; Kantarjian HM
    Cancer; 1995 Jan; 75(2):464-70. PubMed ID: 7812917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
    Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
    Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase.
    Morris SW; Daniel L; Ahmed CM; Elias A; Lebowitz P
    Blood; 1990 May; 75(10):2035-41. PubMed ID: 2337672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W
    Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular studies of chronic myelogenous leukemia using the polymerase chain reaction.
    Nakamura K; Miyashita T; Ozaki M; Iwaya M; Nakazawa S; Okamura J; Kamada N; Tanaka K; Kobayashi N; Mizutani S
    Cancer; 1991 Dec; 68(11):2426-30. PubMed ID: 1933779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duplication of small segments within the major breakpoint cluster region in chronic myelogenous leukemia.
    Litz CE; McClure JS; Copenhaver CM; Brunning RD
    Blood; 1993 Mar; 81(6):1567-72. PubMed ID: 8453102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients.
    Mills KI; MacKenzie ED; Birnie GD
    Blood; 1988 Oct; 72(4):1237-41. PubMed ID: 3167206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cytogenetics of chronic myeloid leukemia with atypical t(6;9) (p23;q34) translocation.
    Jadayel D; Calabrese G; Min T; van Rhee F; Swansbury GJ; Dyer MJ; Maitland J; Palka G; Catovsky D
    Leukemia; 1995 Jun; 9(6):981-7. PubMed ID: 7596189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple strategy for breakpoint fragment determination in chronic myeloid leukemia.
    Kamel AM; Shaker HM; GadAllah FH; Hamza MR; Mansour O; El Hattab OH; Moussa HS
    Cancer Genet Cytogenet; 2000 Oct; 122(2):110-5. PubMed ID: 11106820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations.
    Verschraegen CF; Kantarjian HM; Hirsch-Ginsberg C; Lee MS; O'Brien S; Rios MB; Stass SA; Keating M; Talpaz M
    Cancer; 1995 Sep; 76(6):992-7. PubMed ID: 8625225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of the breakpoint sites within the M-BCR in 50 patients from Argentina with chronic myeloid leukemia.
    Giere IA; Larripa IB
    Leuk Lymphoma; 1996 Aug; 22(5-6):519-22. PubMed ID: 8882967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia.
    Rozman C; Urbano-Ispizua A; Cervantes F; Rozman M; Colomer D; Féliz P; Pujades A; Vives Corrons JL
    Leukemia; 1995 Jun; 9(6):1104-7. PubMed ID: 7596178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of pulsed field gel electrophoresis to characterize BCR gene involvement in CML patients lacking M-BCR rearrangement.
    Min GL; Martiat P; Pu GA; Goldman J
    Leukemia; 1990 Sep; 4(9):650-6. PubMed ID: 2395384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.